Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625898 · ClinicalTrials.gov registry record · Phase 3
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
A Phase 3 study, sponsored by NSABP Foundation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3,509
- Enrollment target
NCT00625898 is a Phase 3 study that was terminated before completion, run by NSABP Foundation. The registered enrollment target is 3,509 participants.
The verdict
NCT00625898, a Phase 3 study, was terminated before completion, sponsored by NSABP Foundation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3,509 participants
- Enrollment target
Study Summary
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Interventions
- DRUG Trastuzumab
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG 5-Fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,509 participants |
| Start Date | 2008-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00625898
The ClinicalTrials.gov registry entry for NCT00625898 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3,509 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT00625898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00625898 about?
NCT00625898 is a clinical study titled "BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab". The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
What is the current status of trial NCT00625898?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3,509 participants. The study started on 2008-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00625898?
The interventions under investigation include: Trastuzumab (DRUG), Bevacizumab (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), 5-Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT00625898?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.